Chemistry:Padsevonil

From HandWiki

Padsevonil (INN, USAN, JAN; developmental code name UCB-0942) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of epilepsy.[1][2][3] It is much more potent than earlier SV2A ligands like levetiracetam and brivaracetam.[3] However, in contrast to its predecessors, padsevonil's chemical structure has been modified such that it is no longer a racetam.[3] In addition, padsevonil also interacts with synaptic vesicle glycoprotein 2B (SV2B) and 2C (SV2C).[3] The drug is being developed by UCB.[1][2] As of November 2023, it is in phase 2 clinical trials.[1][2]

References

  1. ↑ 1.0 1.1 1.2 "Padsevonil". 5 November 2023. https://adisinsight.springer.com/drugs/800033834. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Padsevonil with Synapse". 8 February 2025. https://synapse.patsnap.com/drug/772ce12fe10843dc801998db442787b4. 
  3. ↑ 3.0 3.1 3.2 3.3 "Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil". Neuroscience Bulletin 40 (5): 594–608. May 2024. doi:10.1007/s12264-023-01138-2. PMID 37897555. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Padsevonil&oldid=4179237"